Form 4: Mirum Pharmaceuticals Director Equity Grant

Director Laura Brege received an equity grant of stock options and deferred stock units from Mirum Pharmaceuticals.

Summary

• Director Laura Brege was granted 3,772 stock options with an exercise price of $101.00.
• Director Laura Brege was granted 1,980 deferred stock units (DSUs).
• Both the stock options and DSUs vest on the first anniversary of the grant date (June 15, 2027), or upon the date of the 2027 annual stockholder meeting, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Market volatility could impact the value of the granted equity instruments.
• The exercise price of $101.00 is subject to market performance.

Future Outlook

The equity grants are subject to standard vesting schedules tied to the 2027 annual meeting or the first anniversary of the grant.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board retention and alignment with corporate performance milestones.

Comparison to Industry Standards

• The use of a mix of stock options and deferred stock units is consistent with compensation structures at mid-cap biopharmaceutical companies.
• Vesting periods of one year for director equity are standard within the industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise or settlement of these equity instruments.

Next Steps

• Vesting of equity instruments on the earlier of the first anniversary or the 2027 annual stockholder meeting.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Director Compensation, Equity Grant, Form 4, Insider Transaction